Genmab to Acquire Merus for USD 8 Billion

HBM Healthcare Investments AG announced that Genmab will acquire Merus, a company from HBM's portfolio, for USD 8 billion in cash. Merus shareholders will receive USD 97 per share, a 41% premium over the recent closing price. HBM Healthcare holds a 1.2% stake in Merus, having invested USD 31.4 million since 2021.

Merus specializes in developing full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Their lead product, Petosemtamab, is a promising bispecific antibody for head and neck cancer, already receiving two Breakthrough Therapy Designations from the FDA for its potential in treating this disease.

This acquisition highlights the strategic interest in oncology, particularly in innovative treatments like Multiclonics®, and reflects Genmab's commitment to expanding its therapeutic offerings.